Instrument Inactif

Autres langues GENFIT Euronext Paris

Actions

GNFT

FR0004163111

Recherche biotechnologique et médicale

Cours en clôture Euronext Paris
- ^PTS	-

11/09	Paris prend un peu de hauteur avant l'inflation américaine	AW
11/09	L'Europe ouvre dans le vert, tente un rebond après la BCE	RE

Autres langues

11/09	Inflation bringt die Wall Street in die Zwickmühle
11/09	Afternoon Meeting: La inflación acorrala a Wall Street
11/09	Inflation Has Wall Street Cornered
11/09	A very bad trip for markets?
11/09	GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
11/09	French and Benelux stocks-Factors to watch on September 11
10/09	Euronext includes Genfit, Inventiva in SBF120 index; Interparfums, Verallia excluded
10/09	GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09	GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
04/09	GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
03/09	GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
03/08	GENFIT : Answers its Investors – Episode #3 - August 3, 2026
08/07	Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
03/07	Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement
02/07	GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
02/07	Genfit Announces U.S. Medicare Coverage and Future Reimbursement for Nashnext, A Non-Invasive Diagnostic Technology to Identify Patients with At-Risk Mash
29/06	Saudi Food and Drug Authority Approves Registration of Aikervo (Elafibranor) for Treatment of Primary Biliary Cholangitis
24/06	Genfit's Investigative Treatment for Bile Duct Cancer Shows Positive Results in Phase 1b Study
23/06	GENFIT Reports Positive Phase 1B Data for GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06	GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
15/06	GENFIT: June 15, 2026 Combined Shareholders Meeting Results
08/06	Genfit Launches Nashnext Test Powered by Nis4 Technology Via Labcorp Ondemand for Identification of At-Risk Mash
08/06	GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
25/05	GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
21/05	Genfit S.A. Reports Revenue Results for the First Quarter Ended March 31, 2026